# Future Cardia

YC Dropout raises $14M to take on the $110B market w/ AI-powered implantable devices

- Canonical URL: https://wefunder.com/futurecardia
- Entity ID: wefunder:company:116478
- Last updated: 2026-06-10T05:00:49Z
- Generated at: 2026-06-10T21:15:25Z

## Quick facts
- 5x Top 10 "Most Raised Reg-CF" NATIONWIDE, 10x "Most Raised" on Wefunder & Kingscrowd "Top Deal"
- Incubated by Johnson & Johnson JLABS, accelerated by Stanford’s StartX
- Backed by Sand Hill Angels (SweetGarden, Ro, Masterclass, Parsley Health and many other major exits)
- Multiple exits & two IPOs achieved by team of experts from Medtronic, Boston Scientific, Stanford
- 39 devices implanted at world-renowned medical centers & 70,000+ hours of cardiac data collected
- Limited players, premium pricing, a high value to patients & physicians with simplicity and accuracy
- $110B implantable medical device market
- Forecasting $40M+ in revenue within five years (not guaranteed)

## Active fundraises
- wefunder:fundraise:64055: 4(a)(6) successful (USD)

## Investor memos
- Sixto Global Capital,  LLC: https://uploads.wefunder.com/uploads/remote_files/889984-1Q9TWw2kZBdsKQkpWNzQ5RhZ/Future_Cardia_Investment_Memo_-_Dec_2024.docx.pdf
- Kingscrowd Capital: https://wefunder.com/updates/176834

## Story
Future Cardia is transforming cardiac care by leveraging AI and connected implants to radically improve patient outcomes.Our tiny, implantable cardiac monitoring device can be implanted in just two minutes during an in-office procedure. Powered by AI, our platform provides near real-time data, enabling early detection and intervention. This reduces unnecessary hospital visits, lowers medical costs, and significantly improves patient quality of life.Led by a team of physicians, scientists, engineers and entrepreneurs with over 200 years of combined expertise in cardiac devices development and cardiology with multiple exits and two IPOs.Sandhill Angels, Johnson & Johnson JLABS & Stanford StartX all agree: Future Cardia is poised to revolutionize the $110B implantable cardiac device market. Future Cardia's unique combination of AI-driven technology and strong clinical validation make us an attractive target for acquisition, or an IPO, potentially comparable to successful exits in the medtech space.Heart disease, a chronic condition, affects billions around the world, resulting in an enormous burden to the patients, loved ones, physicians and health care as a whole. Comorbidities further exacerbate the risk of heart disease, and heart failure. A lack of remote heart failure monitoring solutions makes it difficult for heart failure patients and healthcare providers to address emergencies. As the heart begins to weaken, fluid slowly accumulates in the lungs, which leads to sudden and severe respiratory distress, and frequent hospitalizations. Families watch helplessly as their loved ones are rushed to the emergency room, and hospitalized even though the patient is experiencing a “false alarm”. Despite advancements in medical technology, treatment options remain limited, expensive, and invasive.The global economic burden of heart failure, including both direct and indirect costs, is estimated to be $346 billion annually (BioMed Central, 2023). This staggering figure includes hospital readmissions, invasive surgeries, long-term care, and lost economic productivity. The true cost is felt by patients and families in the loss of cherished moments that could have been preventable. Future Cardia is transforming the reality of cardiac care with an AI-powered cardiac monitoring platform. Our implantable, connected cardiac devices monitor and manage heart conditions in real time, setting a new standard in personalized healthcare. Equipped with multi-sensors, Future Cardia devices continuously gather critical data, enabling remote monitoring and timely interventions.By leveraging AI, Future Cardia allows physicians to detect early signs of deterioration and recommend preventative treatments before symptoms arise. Using our platform is simple. The device seamlessly connects to the patient's smartphone, which then securely transmits data to our cloud-based machine-learning platform. Clinicians access this platform through a secure web portal, ensuring comprehensive and real-time patient care.Future Cardia's system records and transmits data on three vital organ functions: electrical activity of the heart (ECG), heart and lung sounds (via an acoustic sensor), and patient activity (through an accelerometer).As we continuously collect more data, the efficacy of our large language models powering ECG and heart sound biomarkers grows, further optimizing the intelligence behind our AI-driven cardiological recommendations.Future Cardia’s multi-sensor, implantable cardiac monitoring device is designed for simplicity and efficiency, taking only two minutes to implant. With Future Cardia, mass adoption is possible, on par with that of a pacemaker.The minimally invasive procedure is performed in-office under local anesthesia. With just one small incision, our device is implanted subcutaneously, requiring no stitches and ensuring a smooth, outpatient experience.Simplicity sets Future Cardia apart. The device requires no input from the patient beyond their smartphone, which is used to inform them about device and cloud connectivity alongside battery health. Physicians benefit from a streamlined monitoring process, receiving only essential data without the need to sift through thousands of pieces of information. With our AI-powered platform, cumbersome and time-consuming cardiac monitoring becomes a thing of the past, delivering a seamless, efficient, and highly effective solution for both patients and doctors.Future Cardia’s patent-pending device is designed with a short regulatory process in mind. Our Class II, 510k classification allows us to move faster than the typical “fast-tracked” FDA approval process, keeping us on schedule for FDA approval and commercialization in 2025.We’re on track to achieving critical medtech milestones: patents, FDA market authorization, and insurance reimbursement. Future Cardia has made significant strides in the development and deployment of our cardiac monitoring technology. In 2024, we successfully implanted our devices in 39 patients, with hundreds more scheduled at medical centers of excellence, demonstrating the safety and efficacy of our technology in real-world settings. We have NDAs with top medical companies. And our AI algorithms are powered by over 60,000 hours of cardiac data. To date we've raised $14M from over 10k investors.Future Cardia is backed by Sandhill Angels and has partnered with Stanford’s Start X and Johnson & Johnson to incubate and accelerate our business. These esteemed partnerships validate our technology and underscores its potential to transform cardiac monitoring. We currently have NDAs with the top five medical facilities in the world, ensuring that our devices are tested and validated in the most rigorous environments.We have already established relationships with leading med tech companies, which positions us well for a strategic acquisition. Alternatively, our robust financial performance and market potential make us a strong candidate for an IPO.Our team is led by experts with 200 years of combined experience, multiple exits, and two IPOs. We have a robust advisory board of top scientists and clinicians from prestigious institutions like Harvard, Stanford, and Johns Hopkins, ensuring we stay at the forefront of innovation.Our track record of success speaks volumes about our ability to deliver results.Our advisory team is composed of world-renowned key opinion leaders, physicians & scientists.The global cardiac implantable devices market is projected to exceed $110B. This growth is driven by the rise of cardiovascular disease, aging populations, and an increasing demand for advanced healthcare solutions. As these trends continue, there is a pressing need for a new market leader to bring innovation to this traditionally stagnant industry.One person dies every 33 seconds from cardiovascular disease (CDC, 2024). Future Cardia’s focus on AI and real-time monitoring sets us apart from traditional cardiac devices. By providing continuous, accurate data, we empower clinicians to make informed decisions and improve patient outcomes. The Journal of Cardiac Failure reported that patients enrolled in a study to gauge the efficacy of remote patient monitoring reported a 52% reduction in total cost of care. Future Cardia is poised to become a huge player this space, improving cardiac monitoring and addressing the urgent needs of healthcare providers and patients alike.Our business model is built on device sales and continued monitoring services directly to healthcare providers. On our devices, our low manufacturing costs ensure an 81% profit margin. And because of existing insurance reimbursements, our healthcare providers will be able to provide the services with delay. We offer comprehensive and continued heart monitoring by analyzing trending changes in cardiac performance.*Projections not guaranteedFuture Cardia has developed a streamlined go-to-market strategy. Initially, our focus will be on the high-volume regions where we project to generate $6.2 million in revenue within the first two years following our launch in 2025. We anticipate that the initial deployment of 5,000 implants will yield approximately $23 million in revenue over a period of four years.As we achieve key milestones, such as FDA approval, product expansion and broader market adoption, we expect our revenue trajectory to accelerate. Our roadmap includes expanding clinical trials, obtaining FDA approval, and scaling production to meet growing demand. We are also focused on continuously enhancing our AI to make monitoring even smarter for all patients and physicians. Achieving FDA clearance is a critical milestone that will validate our technology and open up significant market opportunities, positioning us for long-term success.

## FAQ
1. **Impressive momentum and backing! Approximately how much more in financing do you anticipate to need to get Future Cardia fully approved and sales started?**
   - Thank you Jason for your support. We are currently raising an additional $5 million, which will enable us to file for FDA clearance and commence commercialization by mid-2025. This timeline and cost are significantly more efficient than many other implantable bioelectric startups, achieving our goals in half the time and at half the cost. Jae B
2. **Hello Jae, would like to invest , May i use Roth Ira account Like last time ??**
   - Hello Peter, We are thankful for your support. I believe it is possible with Wefunder as well. Feel free to proceed, and I will double check on my side as well.
3. **Shouldn't it be called a "minimally-invasive procedure" instead of a "non-invasive procedure" when implanting the device? You state: "The non-invasive procedure is performed in-office under local anesthesia. With just one small incision, our device is implanted subcutaneously,...**
   - Hi Dan, It is fixed. Thank you again for flagging it for us!
4. **So when the battery runs out after two years I assume the implant device has to be removed to replace the battery and then reinserted back into the body. Correct?**
   - Hi Dan, Yes. correct. our implant and explant procedures are the same as the rest. Jae b
5. **Hi Jaeson, are you aware of Ilika's "Stereax Solid State Batteries"? These may be of interest as your product seems to require safe, long lasting batteries. : https://www.ilika.com/micro-solid-state-batteries Ilika is a listed co. Regards.**
   - Hi Dion, We love Solid State Batteries, however, they are not ready for the prime time... And we know iLika well. However, Those are at the experimental stage and not ready for the prime time yet.

## Team
- Jaeson Bang (Founder & CEO )
- Anatoly Yakovlev, PhD (Data Scientist)
- Adam Gullickson (VP of Operations)
- Steve Zielinksi (VP of Systems Engineering and Software)
-  Dimitrios Georgakopoulos, PhD (Science Advisor)
- Dr. Dan Burkhoff, MD PhD (Medical Advisor)
- Dr. Kevin Heist, MD PhD (Medical Advisor)
- Dr. Toshi Okabe, MD (Medical Advisor)

## Recent posts
- Future Cardia Discover Recording (2024-10-08T16:38:08Z)

## Q&A
- Q: Hello, What is the minimum investment needed to be part of Future-Cardio?
  - A: Hi Erik, Thank you for your investment consideration. $100 is the minimum via Wefunder. Hope to earn your investment! Jae B
- Q: Shouldn't it be called a "minimally-invasive procedure" instead of a "non-invasive procedure" when implanting the device? You state: "The non-invasive procedure is performed in-office under local anesthesia. With just one small incision, our device is implanted subcutaneously, requiring no stitches and ensuring a smooth, outpatient experience." Minimally invasive surgery (MIS) is a surgical technique that uses small incisions and a few stitches to reduce trauma to the body. MIS can also be called laparoscopic or keyhole surgery.
  - A: Hi Dan, It is fixed. Thank you again for flagging it for us!
  - A: HI Dan, You are correct. It is Minimally Invasive... we will get it fixed right away. Huge thanks.
- Q: Hello, I want to invest. To be honest just to make my savings grow. I thought about crypto but investing in a real company that actually does something useful makes more sense. Can you give some insight in to how risky this investment is, can I potentially lose the whole investment and is this likely to happen? What do I get in return for investing, stocks? Lets say I invest €5000,-. In a realistic scenario, what could this turn into 5 years down the road? Thanks. Kind regards
  - A: Hello KV, Thank you for reaching out and considering investing in our company. Risk: As with any startup investment, there is inherent risk. While we have made significant progress, such as implanting our device in 39 patients and raising nearly $14 million to date, investing in early-stage companies is unpredictable. Returns: By investing, you would receive equity in the form of shares in the company. This means you become a partial owner and would benefit from any increase in the company’s valuation, either through growth or an eventual acquisition/exit event. Realistic Scenario for €5,000: Our goal is to grow the company significantly as we approach FDA approval and expand our product capabilities. If successful, investments could multiply several times over within 5–7 years, though this is not guaranteed. Hope this helps. I would welcome an opportunity to earn your investment. Thank you. Jae b
- Q: How does this differ from the Medtronic Linq system? What's the differentiator? Also is it MRI compatible?
  - A: Hi Kevin, Thank you for your question. Future Cardia's system offers several differentiators compared to Medtronic's LINQ system, particularly in the areas of wireless connectivity, ECG clarity, manufacturing efficiency, and user experience. 1. Superior Wireless Connectivity: 2. Clearer ECG Signal: 3. Balanced Manufacturing Approach: 4. Simpler User Experience (UX): As you probably know, none of these features will drive purchasing decisions. This space is heavily reliant on a combination of clinical outcomes, business strategy, and service-focused operations that bring tangible value to both patients and physicians. Success in this market requires demonstrating long-term clinical impact on patient health, providing robust business support for healthcare organizations, and offering strong service models that simplify device management and enhance physician efficiency. Regarding MRI compatibility, all modern implantable devices are MRI compatible. However, Future Cardia is targeting MRI safety, which goes beyond compliance and offers an additional competitive edge. Hope this helps. Thank you. Jae B
- Q: I’d love to understand why the device is so much more accurate even though it is so close to the skin. Does that little layer make so much of a difference?
  - A: Hi Lyndia, Generally speaking, accuracy improves as the device gets closer to the body, especially when sensing electrical and mechanical aspects. For example, a device 10 feet away from the body is likely to perform far worse than one that is directly on the body. Among devices worn on the body, those with minimal movement (like a sticky patch) tend to perform better than those with more movement (such as a loosely worn watch). Implanted devices (like Future Cardia, pacemakers, and defibrillators) outperform even sticky patches by a significant margin. I hope this helps! Best, Jae B
- Q: Hi Jaeson, are you aware of Ilika's "Stereax Solid State Batteries"? These may be of interest as your product seems to require safe, long lasting batteries. : https://www.ilika.com/micro-solid-state-batteries Ilika is a listed co. Regards.
  - A: Hi Dion, We love Solid State Batteries, however, they are not ready for the prime time... And we know iLika well. However, Those are at the experimental stage and not ready for the prime time yet.
- Q: So when the battery runs out after two years I assume the implant device has to be removed to replace the battery and then reinserted back into the body. Correct?
  - A: Hi Dan, Yes. correct. our implant and explant procedures are the same as the rest. Jae b
- Q: Impressive momentum and backing! Approximately how much more in financing do you anticipate to need to get Future Cardia fully approved and sales started?
  - A: Thank you Jason for your support. We are currently raising an additional $5 million, which will enable us to file for FDA clearance and commence commercialization by mid-2025. This timeline and cost are significantly more efficient than many other implantable bioelectric startups, achieving our goals in half the time and at half the cost. Jae B
- Q: Are you filling for European registration ? Regards Dr C
  - A: Hi Richard, Europe( and Asia too) are very much on our radar. For now, we will focus on the FDA submission and then expand to EU and Asia. Let me know if a short call would be helpful. Feel free to email me and let's coordinate. jaeson.bang@futurecardia.com Thank you. Jae b
- Q: Jae, when will you have a update of progress and any related timeline of next steps Tks Mike K
  - A: Hi Michael, One of our major milestones for 2025 is submitting our findings to the FDA—this alone represents a significant value inflection point and a major de-risking event for potential acquirers. In the meantime, we’re on track to conclude our human testing by mid-June and will begin preparing all documentation for our targeted November submission. Our implantable battery development will also reach its midpoint around the same time. There are several smaller goals we’re pursuing as well, but I’ll keep this update focused on the big picture. Oh.. feel free to ping me anytime. Jaeb@futurecardia.com Thank you. Jae B
- Q: I invested last year, and have not received any information, none at all!!~ At the time of my investment the minimum was $304.00. I may need to give you a new email address.Please call or send me info by USPS mail. Thanks!
  - A: Hi Tim, I have been sending 1-2 updates a week for the past several months. And big updated at every month. We never had an offer min of $304. It was at one point $100, 250. and now 348. please email me - jaeson.bang@futurecardia.com This way we can sort it out in private. Thank you. jae b
- Q: What is the price per share of proposed
  - A: Hi John, it is $3 per share. Hope to earn your investment. Thank you. Jae B
- Q: Hello Jaeson, Great traction, love the solution. I made a token investment, might consider increasing depending upon further research. Couple of questions - Are you looking at alternative logics (neuromorphic based sensor) to extend the battery life. 2yrs is too short to go through a repeat procedure and replace a device. I am unsure how much this would cost the patient even if the insurance covers it. The cost seems prohibitively high to replace every 2 years. There are companies that are breaking new ground in neuromorphic space (bringing 5 to 10x power save), let me know if you need introductions. - How is your current implant feedback coming along? It would be great to have a view of learnings from your 39 implants. Thanks in advance for answering my questions.
  - A: Hello Prakash, Thank you for your investment and continued interest in our progress. Our next-generation battery will be ready by mid-2025, extending the device’s lifespan to 5 years. Additionally, with updated chips and an enhanced design, we are targeting a further 15% improvement in longevity. As a fast follower in this space, we are positioning our pricing competitively at $5,000 per unit. Since this category already has established reimbursement pathways, insurance typically covers around $8,000 per procedure, which greatly offsets the costs for patients. Regarding neuromorphic sensors, I’d definitely welcome an introduction. I’m very interested in exploring this space further. Please feel free to reach out to me directly at jaeb@futurecardia.com. On the implant front, all 39 patients are doing well. We’ve encountered occasional internet connection issues, but they’ve been easily resolved by reconnecting to the network. This has been a valuable learning experience and has reinforced the impact we’re delivering to both patients and physicians. Thank you again for your support. Best regards, Jae B jaeb@futurecardia.com
- Q: Do you have clinical data especially outcome data regarding heart failure readmission. I’m not able to find any trials or I’m asking the wrong question and you are submitting for fda approval to trial the device
  - A: Hi Muhammad, Great point. As a fast follower in the implantable bioelectric space (510K with insurance coverage), we are not required to conduct a clinical trial. Additionally, the predicate devices also did not undergo clinical trials. Our procedure and indication are equivalent to the LINQ device. Our primary goal is to enter the AFIB monitoring space, with plans to expand into HF monitoring. Hope this helps. Thank you. Jae B
- Q: As a multi-investor in Future Cardia, I'm not only incredibly excited about the future of this innovative company but also deeply invested in its success. Having witnessed the company's progress firsthand, I'm even more confident that their AI-powered implantable cardiac monitoring devices have the potential to revolutionize cardiac care and improve the lives of millions of people around the world. I'm particularly impressed by Future Cardia's focus on remote monitoring and timely interventions. This could significantly reduce the number of hospitalizations and deaths from cardiac events. Additionally, the company's commitment to making its devices affordable and accessible to all patients is commendable. I'm not just an investor in Future Cardia; I'm a believer in their mission. I'm confident that Future Cardia has a bright future ahead and I'm proud to be a part of their journey. I encourage you to learn more about this amazing company and consider investing in their future.
  - A: Thank you so much for your kind words Barrington. Our goal is to get us to 510K clearance in 2025! I will deliver! Jae B